ClinicalTrials.gg
RecruitingNCT07397949Updated Nov 19, 2026

Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery

A Phase 4 interventional study of Rebamipide 2% ophthalmic solution and Diquafosol 3% ophthalmic solution in Dry Eye Disease (DED) and Cataract, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing rebamipide in Dry Eye Syndromes — 1 open to participants now, 1 under way, none of them phase 3. rebamipide · Dry Eye Syndromes.

Planned enrollment
11th of 14
60 · median 171
Started
2026
the only one that year
Phase 4
4 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
2 of 14
Samsung Medical Center

Among the 14 studies testing rebamipide in Dry Eye Syndromes, this one is the 11th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 4, and was the 13th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 14 studies testing rebamipide in Dry Eye Syndromes is open now, in 1 country.

By country, each count listing its studies:

About rebamipide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing rebamipide in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This clinical trial is designed to compare two commonly used eye drop treatments for dry eye disease in patients undergoing cataract surgery.

Dry eye disease is common in people who need cataract surgery and may worsen before or after surgery, causing eye discomfort, blurred vision, and unstable vision. Proper management of dry eye before and after surgery may help improve eye comfort and the accuracy of vision outcomes.

In this study, patients with mild to moderate dry eye disease who are scheduled for cataract surgery will be randomly assigned to receive one of two treatments:

Rebamipide eye drops, or

Diquafosol eye drops

Participants will begin using the assigned eye drops one month before cataract surgery and continue treatment for three months after surgery. The eye drops will be used only in the eye undergoing surgery.

Researchers will examine whether one treatment is as effective as the other in improving tear film stability and reducing dry eye symptoms around the time of cataract surgery. Eye examinations and questionnaires will be performed before surgery, on the day of surgery, and during follow-up visits after surgery.

The information gained from this study may help doctors choose the most appropriate treatment for managing dry eye disease in patients undergoing cataract surgery.

Read the detailed description

Dry eye disease (DED) is frequently observed in patients undergoing cataract surgery and may be exacerbated by surgical trauma, postoperative inflammation, and disruption of corneal innervation. Worsening of dry eye symptoms during the perioperative period can negatively affect patient comfort, tear film stability, and visual outcomes after surgery. Therefore, effective perioperative management of dry eye disease is an important component of cataract surgery care.

This study is a prospective, randomized, parallel-group, investigator-initiated clinical trial designed to compare the efficacy of rebamipide 2% ophthalmic solution and diquafosol 3% ophthalmic solution for perioperative management of dry eye disease in patients undergoing cataract surgery.

Eligible adult patients with mild to moderate dry eye disease who are scheduled for unilateral cataract surgery will be randomly assigned in a 1:1 ratio to one of two treatment groups. Participants will receive either rebamipide or diquafosol eye drops administered to the surgical eye, starting one month before cataract surgery and continuing for three months postoperatively. Standard postoperative medications for cataract surgery will be administered according to routine clinical practice.

The primary outcome measure is the change in tear film breakup time (TBUT) from baseline to the postoperative period. Secondary outcome measures include changes in corneal staining grade, patient-reported symptoms assessed using the Ocular Surface Disease Index (OSDI), tear secretion measured by Schirmer's test, ocular surface inflammation assessed by tear matrix metalloproteinase-9 (MMP-9), corneal topography, optical biometry parameters, meibomian gland function, and patient-reported discomfort related to eye drop use.

Clinical assessments will be conducted at baseline, on the day of surgery, and at postoperative follow-up visits according to the study schedule. Safety will be monitored throughout the study by assessing adverse events and ocular findings at each visit.

This study aims to determine whether rebamipide is non-inferior to diquafosol in maintaining tear film stability and improving dry eye symptoms during the perioperative period of cataract surgery, thereby providing evidence to guide optimal dry eye management strategies in this patient population.

03

Conditions studied

  • Dry Eye Disease (DED)
  • Cataract
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 40 years or older scheduled for unilateral cataract surgery
  • Presence of dry eye disease, defined by an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:

    • Tear film breakup time (TBUT) ≤7 seconds
    • Oxford corneal staining grade ≥1
    • Schirmer's test value ≤10 mm/5 minutes
  • Ability and willingness to comply with the study protocol and follow-up schedule
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Active ocular infection or inflammation, including infectious keratitis
  • History of ocular surgery other than cataract surgery in the study eye
  • Use of topical medications that may affect the ocular surface (e.g., intraocular pressure-lowering eye drops)
  • Any ocular or systemic condition judged by the investigator to interfere with study participation or outcome assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Rebamipide Group

    Participants receive topical rebamipide 2% ophthalmic solution administered four times daily to the surgical eye, starting 1 month before cataract surgery and continuing for 3 months postoperatively.

    Drug: Rebamipide 2% ophthalmic solution

  • Active comparator
    Diquafosol Group

    Participants receive topical diquafosol 3% ophthalmic solution administered four times daily to the surgical eye, starting 1 month before cataract surgery and continuing for 3 months postoperatively.

    Drug: Diquafosol 3% ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Tear Film Breakup Time (TBUT)

    Change in tear film breakup time (TBUT) from baseline to the postoperative period, comparing rebamipide and diquafosol for perioperative management of dry eye disease in patients undergoing cataract surgery.

    Time frame: From baseline to postoperative 1 month

Secondary outcomes

  1. Change in Ocular Surface Disease Index (OSDI) Score

    Change in patient-reported ocular symptoms assessed using the Ocular Surface Disease Index (OSDI) questionnaire, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy. The OSDI score ranges from 0 to 100, with higher scores indicating more severe ocular surface symptoms (worse outcomes).

    Time frame: From baseline to postoperative 1 and 3 months

  2. Change in Corneal Staining Grade (Oxford Scale)

    Change in corneal epithelial staining graded using the Oxford grading scale (0-5) following fluorescein staining, comparing ocular surface staining severity between treatment groups. Higher grades indicate more severe corneal epithelial staining (worse outcomes).

    Time frame: From baseline to postoperative 1 month

  3. Change in Schirmer's Test Value

    Change in tear secretion measured by Schirmer's test without anesthesia.

    Time frame: From baseline to postoperative 1 and 3 months

  4. Change in Tear Matrix Metalloproteinase-9 (MMP-9) Level

    Change in tear matrix metalloproteinase-9 (MMP-9) levels assessed using a commercially available tear MMP-9 test.

    Time frame: From baseline to postoperative 1 and 3 months

07

Study locations

1 of 1 sites recruiting
  • Samsung Mec
    Seoul, Seoul, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — The detailed study protocol and the data that support the findings of this study are available from the corresponding author upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 7 months is below that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → May 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 9, 2026
StartActual
May 11, 2026was Mar 2026
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
Samsung Mec is now Recruiting
Nov 19, 2026
Start date
Mar 2026→May 11, 2026 (actual)
Nov 19, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionChange in Corneal Staining Grade (Oxford Scale): how it is measured was reworded
  • DescriptionChange in Ocular Surface Disease Index (OSDI) Score: how it is measured was reworded
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    Samsung Mec is now Recruiting
    Start date Mar 2026→May 11, 2026 (now actual)
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionChange in Corneal Staining Grade (Oxford Scale): how it is measured was reworded
    • DescriptionChange in Ocular Surface Disease Index (OSDI) Score: how it is measured was reworded
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07397949
Responsible party
Dong Hui Lim (Associate Professor, Samsung Medical Center) — Principal investigator
First posted
Feb 9, 2026
Start date
May 11, 2026
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Dong-Hui Lim, MD, PhD
Contact
ldhlse@gmail.com
+82 2-3410-5478

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rebamipide

Start the discussion